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Background: In HIV-infected persons, good adherence to antiretroviral therapy (ART) is essential for successful
treatment outcomes. Patients’ worries before starting ART may affect their ART adherence and treatment outcomes.
Methods: Between 2004 and 2009, HIV-infected individuals in a prospective cohort study in rural Uganda were
assessed for ART eligibility. A counsellor explained the ART eligibility criteria, adherence and side effects, and
recorded the patients’ worries related to ART. Every quarter, patients who initiated ART had clinical, immunological
(CD4 cell counts) and virological (viral loads) assessments, and data were collected on ART adherence using
patients’ self-reports and pill counts. We describe the patients’ worries and examine their association with ART
adherence, and immunological and virological outcomes.
Results: We assessed 421 patients, 271 (64%) were females, 318 (76%) were aged 30 years and above and 315
(75%) were eligible for ART. 277 (66%) reported any worry, and the proportions were similar by sex, age group and
ART eligibility status. The baseline median CD4 counts and viral loads were similar among patients with any worry
and those with no worry. The commonest worries were: fear of HIV serostatus disclosure; among 69 (16%)
participants, lack of food when appetite improved after starting ART; 50 (12%), concurrent use of other medications;
33 (8%), adherence to ART; 28 (7%) and problems concerning condom use; 27 (6%). After 24 months or more on
ART, patients who reported any worry had made more scheduled ART refill visits than patients who reported no
worry (p<0.01), but the annual CD4 cell increases were similar (p=0.12). After one year on ART, patients who
reported any worry had greater virological suppression than patients who reported no worry (p<0.05).
Conclusions: Despite the lack of significant associations of worries with unfavourable ART outcomes, physicians
and counsellors should assist patients in overcoming their worries that can cause stress and discomfort. Food
supplements may be desirable for some patients initiating ART.
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Eligible Not eligible Total
n (%) n (%) n (%)
Total 217 (52) 204 (48) 421 (100)
Gender
Males 79 (36) 71 (35) 150 (36)
Females 138 (64) 133 (65) 271 (64)
WHO clinical stage
1 38 (18) 109 (53) 147 (35)
2 64 (29) 67 (33) 131 (31)
3 81 (37) 28 (14) 109 (26)
4 34 (16) 0 (0) 34 (8)
Age (years)
13-19 7 (3) 3 (1) 10 (2)
20-29 53 (24) 40 (20) 93 (22)
30-39 81 (37) 90 (44) 171 (22)
40 + 76 (35) 71 (35) 147 (35)
Mean (SD) 37.0 (11.8) 37.0 (10.4) 37.0 (11.1)
Median [IQR] 35.0 [29-43] 36.0 [30-43] 35.0 [30-43]
Range 14 – 78 14 – 72 14-78
CD4 cell counts/μL1
<200 186 (86) 0 (0) 186 (45)
≥200 30 (14) 202 (100) 232 (56)
Mean (SD) 127 (155) 519 (254) 317 (287)
Median [IQR] 114 [37-179] 466 [314-663] 225 [107-466]
Range 1 – 1764 201 – 1298 1-1764
SD - standard deviation IQR - inter-quartile range.
1One person eligible for ART had CD4 missing while 2 people not eligible for
ART had CD4 missing.
Some percentages do not add up to exactly 100 because of rounding
off errors.
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In HIV-infected persons, good adherence to antiretro-
viral therapy (ART) is essential for successful treatment
outcomes and improved quality of life with reduced
morbidity and mortality [1-3]. Poor ART adherence is
associated with perceived HIV stigma among patients re-
ceiving ART [4], being single (never married) and belief
in divine spiritual healing in Uganda [5,6], and in Cote
d’Ivoire, fear of treatment side effects and use of trad-
itional healers [7]. Good ART adherence was associated
with formal education level in Nigeria [8] and concerns
for family well being in Uganda [9]. Common barriers to
ART adherence in developed and developing countries
were found to be; fear of disclosure, forgetfulness, lack
of understanding of treatment benefits and leaving be-
hind medications, while problems of access, including fi-
nancial constraints and disruption in drug supplies were
specific to developing countries [10].
There are no published reports that have described pa-
tients’ worries before starting ART and how they affect ART
adherence and treatment outcomes, because most studies
on ART adherence have been among patients already on
ART. However, prior to starting ART, it is important to as-
sess patients’ beliefs and knowledge about ART to prepare
them for the life-long treatment and to enhance adherence
[11,12]. We describe the worries reported by adult patients
at the first assessment for ART eligibility and also examine
the possible association of these worries with; ART adher-
ence, and immunological and virological ART outcomes.
This information will be useful in the counselling and as-
sessment of patients for the lifelong ART.
Methods
In January 2004, free ART was introduced for eligible
participants in a prospective HIV-1 clinical cohort and
general population cohort in rural Uganda [13-15]. Par-
ticipants’ assessment for ART eligibility involved ART
counselling on: eligibility criteria, life-long treatment, ef-
fects and side-effects, adherence, safe sex practices, nu-
trition, contraception, HIV serostatus disclosure, need
for treatment supporter and couple counselling. At the
assessment for ART eligibility, participants’ questions,
concerns, worries or comments related to ART were
recorded on a standardized check-list form. World
Health Organisation (WHO) HIV clinical staging [16]
and CD4 cell count measurements were done, and
cotrimoxazole prophylaxis was provided [17]. Partici-
pants who were not yet eligible to start ART were given
a date for future reassessment while eligible participants
initiated ART according to the Uganda National ART
guidelines [18,19]. Participants were reviewed quarterly
for clinical and laboratory assessment, monthly for ART
refills and whenever they fell sick. We defined patient’s
worries before starting ART as the patient’s reportedquestions, worries, concerns and comments regarding
ART during the first ART eligibility assessment.Categorisation of participants’ worries
Although participants asked open questions or expressed
their worries or concerns openly, these were categorised
as worries related to: (a) Fear of HIV serostatus disclos-
ure by the patient. (b) Food and nutrition; worry over
lack of food when appetite improved while receiving
ART. (c) Condom use; concerns or worries about using
condoms; either avoiding disclosing HIV serostatus, not
knowing how to use them, or reluctance to use them.
(d) Concurrent use of other medications like cotrimoxazole
prophylaxis, anti-tuberculosis drugs, anti-hypertensive
drugs, herbal medications etc. (e) Worry about ART adher-
ence; especially taking the ART medications promptly and
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fects. (g) Whether ARVs will actually improve their health
(regain strength and weight). (h) Failure to identify a treat-
ment supporter. (i) Contraception /child bearing; concerns
whether one would improve and be able bear a child, and
what interval one can take to conceive after starting ART.
Measurement of outcomes
The primary outcome measure was ART adherence
while the secondary outcome measures were the im-
munological (CD4 cell counts), virological (viral loads)
treatment outcomes, ART side effects and death. At each
ART refill visit, we collected ART adherence data on:
whether the participant was late for the ART refill visit,
the number of days the participant missed taking pills,
reasons for missing pills and did a pill count. Data was
collected on any side effects related to ART and also on
deaths that occurred after starting ART. A full blood
count was done at ART initiation, one month and quar-
terly. CD4 cell counts were measured at ART initiation
and quarterly using the FACS Count method (Becton
Dickinson, San Jose, CA, USA), with external qualityTable 2 Distribution of patients’ worries at the first assessme
Patient’s reported worries Total ART eligi
Eligible No
n (%) n (%) n
Total 421 217 204
Any worry 277 (66) 141 (65) 136
HIV serostatus disclosure 69 (16) 38 (18) 31
Food and nutrition 50 (12) 25 (12) 25
Use of other medications 33 (8) 20 (9) 13
ART adherence 28 (7) 14 (6) 14
Condom use 27 (6) 13 (6) 14
ARV side effects 23 (5) 15 (7) 8
Will ARVs make me better? 20 (5) 13 (6) 7
Treatment supporter 13 (3) 4 (2) 9
Contraception /child bearing 14 (3) 6 (3) 8
Will ARVS make me worse? 13 (3) 5 (2) 8
Residence outside study area 12 (3) 4 (2) 8
Alcohol use 11 (3) 4 (2) 7
Why not start ART immediately 11 (3) 4 (2) 7
Employment/work issues 6 (1) 4 (2) 2
Spouse’s HIV serostatus 5 (1) 3 (1) 2
Pill burden 3 (1) 3 (1) 0
HIV-related stigma 3 (1) 2 (1) 1
Cigarette smoking 1 (0) 0 (0) 1
Others 50 (12) 23 (11) 27
* Fisher’s exact test.
Note: numbers do not add up as some patients had more than one worry.control from the United Kingdom External Quality Assur-
ance Scheme (UKNEQAS). Viral loads were measured at
ART initiation and every 6 months. From January 2004
to September 2007, we used the VERSANT RNA 3.0
(Bayer, Bayer HealthCare, NY, USA) assay (lower de-
tection limit of 50 copies/ml). While from October
2007, we used the COBAS Amplicor MONITOR 1.5
(Roche, Roche Molecular Systems, NJ, USA) assay
(lower detection limit of 400 copies/ml). External quality
assurance was from the Virology Quality Assurance
Scheme (Rush University, Chicago, IL) and UKNEQAS.
Statistical analysis
Data was managed using a Microsoft Access data base and
analysed using Stata version 11. Baseline characteristics,
WHO HIV clinical stage, CD4 cell counts and log viral
loads of participants who reported ART worries and those
who reported no worries were compared. Overall and spe-
cific worries were examined by ART eligibility status and
gender. We used two approaches to compare ART adher-
ence among those with no worry and those with one worry
or more; (a) we compared the proportion of patients whont for ART eligibility; by eligibility status and gender
bility status Gender
t eligible p-value Males Females p-value
(%) n (%) n (%)
150 271
(67) 0.715 95 (63) 182 (67) 0.428
(15) 0.521 23 (15) 46 (17) 0.663
(12) 0.816 14 (9) 36 (13) 0.230
(6) 0.278 14 (9) 19 (7) 0.396
(7) 0.886 8 (5) 20 (7) 0.420
(7) 0.715 11 (7) 16 (6) 0.566
(4) 0.177 4 (3) 19 (7) 0.600
(3) 0.217 6 (4) 14 (5) 0.590
(4) 0.128 5 (3) 8 (3) 0.829
(4) 0.508 3 (2) 11 (4) 0.259
(4) 0.338 4 (3) 9 (3) 0.710
(4) 0.200 1 (1) 11 (4) 0.063*
(3) 0.307 7 (5) 4 (1) 0.049
(3) 0.307 4 (3) 7 (3) 0.959
(1) 0.455 4 (3) 2 (1) 0.110
(1) 0.990* 2 (1) 3 (1) 0.990 *
(0) 0.249* 1 (1) 2 (1) 0.990*
(0) 0.599 0 3 (1) 0.196
(0) 0.485* 1 (1) 0 0.356 *
(13) 0.403 15 (10) 35 (13) 0.376
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and (b) also the proportions with any self-reported late-
ness for appointment at least once, having missed ART
doses in 4 days prior to the visit and having missed ART
doses in the weekend prior to the visit. Mean CD4 in-
crease and median log viral load decrease were compared
between patients with worries and those with no worry,
and between patients with a specific worry and all those
without that specific worry. Proportions were compared
using the Chi squared tests except where a specific worry
was reported by fewer than 5 patients when Fisher’s Exact
test was used. We assessed the association between pa-
tients’ worries and; ART adherence, immunological out-
comes, virological outcomes, ART side-effects and death,
adjusting for potential confounders; age, sex, WHO HIV
clinical stage and CD4 cell counts.
Ethical consideration
The study was approved by the Science and Ethics com-
mittee of the Uganda Virus Research Institute and by the
Uganda National Council for Science and Technology.
Participants gave informed written consent for participa-
tion in the study and confidentiality was ensured
throughout the study.
Results
Between January 2004 and October 2009, we assessed
421 HIV-infected individuals for ART eligibility: 271






One worry or more
N=205 (65%)







Figure 1 Flow chart of study participants.older (Table 1). The age distribution of individuals who
were eligible to start ART at the first assessment for
ART eligibility and those who were not eligible was simi-
lar (Table 1). There were no significant differences in the
distribution of ART eligibility status, patients’ gender,
median CD4 cell counts and median viral loads between
individuals who had no worries and those who had one
worry or more. Of 421 people assessed for ART eligibil-
ity, 277 (66%) expressed one worry or more about taking
ART. The commonest worries reported were: fear of
HIV serostatus disclosure in 69 (16%) patients, lack of
food when appetite improved in 50 (12%), concurrent
use of other medications in 33 (8%), ART adherence in
28 (7%), condom use (avoiding disclosing HIV
serostatus, not knowing how to use them, or reluctance
to use them) in 27 (6%), and antiretroviral (ARV) drug
side-effects in 23 (5%) (Table 2).
Of the 421 patients assessed for ART eligibility, 315
(75%) were found to be eligible for ART (217 at the first
assessment and 98 at a subsequent one). By October 2009,
of the 315 patients found to be eligible for ART, 299 (95%)
[104 (35%) with no worry and 195 (65%) with one or more
worries] started ART had started ART (Figure 1) and 225
(71%) had completed 12 months of follow-up while 172
(55%) had completed at least 24 months of follow-up.
Among the 225 patients who had completed 12 months
on ART, there was no association between ART adherence
and prior worries about ART (Table 3). However in the
172 patients who had completed 24 months on ART, aT eligibility
1












Table 3 ART adherence in patients with and without worries, and those with selected specific worries stratified by
duration on ART

















n=110 n=205 n=54 n=38 n=23 n=26 n=19 n=19
No of participants: n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Eligible but not yet started ART 6 (5) 10 (5) 3 (6) 0 (0) 0 (0) 2 (8) 0 (0) 0 (0)
Started < 12 months ago 28 (25) 46 (22) 12 (22) 9 (24) 4 (17) 6 (23) 2 (11) 7 (37)
Started 12-24 months 24 (22) 29 (14) 7 (13) 7 (18) 6 (26) 3 (12) 3 (16) 1 (5)
Completed 24 months 52 (47) 120 (59) 32 (59) 22 (58) 13 (57) 15 (58) 14 (74) 11 (58)
Patients who had completed 12 months on ART 76 149 39 29 19 18 17 12
No of scheduled visits in first year
<9 visits 31 (41) 55 (37) 14 (36) 6 (21) 9 (47) 6 (33) 6 (35) 5 (42)
9-10 visits 20 (26) 45 (30) 12 (31) 12 (41) 3 (16) 3 (17) 7 (41) 5 (42)
11 or more 25 (33) 49 (33) 13 (33) 11 (38) 7 (37) 9 (50) 4 (24) 2 (17)
Self-reported ART adherence
Late for appointment at least oncea 0 0 0 0 0 0 0 0
Missed doses in 4 days prior to visit 18 (24) 27 (18) 8 (21) 3 (10) 4 (21) 5 (28) 3 (18) 3 (25)
Missed doses in weekend prior to visit 0 0 0 0 0 0 0 0
Patients who had completed 24 months on ART 52 120 32 22 13 15 14 11
No of scheduled visits # *
<20 22 (42) 60 (50) 17 (53) 9 (41) 6 (46) 6 (40) 5 (36) 7 (64)
20-22 27 (52) 34 (28) 7 (22) 9 (41) 4 (31) 3 (20) 6 (43) 3 (27)
≥23 3 (6) 26 (22) 8 (25) 4 (18) 3 (23) 6 (40) 3 (21) 1 (9)
Self-reported ART adherence
Late for appointment at least once 0 0 0 0 0 0 0 0
Missed doses in 4 days prior to visit 19 (37) 38 (32) 14 (44) 6 (27%) 4 (31) 3 (20) 4 (29) 3 (27)
Missed doses in weekend prior to visit 0 0 0 0 0 0 0 0
Note: comparisons are between those with one or more worries and those with no worry, and also between those with a particular worry and all those without
that particular worry.
a 4 missing data for all adherence data (late appointments, missed doses) in the first year.
* p<0.01.
# Comparisons using chi-squared test on 2 degrees of freedom, comparing the percentage in each of the three categories.
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one worry or more had attended 23 or more scheduled
visits compared to 6% (3/52) among those without any
worry (p<0.01). There was no association between the
self-reported ART adherence measures and having any
specific worry among patients who had completed either
12 or 24 months on ART.
Of the 299 patients who started ART (104 with no
worry and 195 with one or more worries), CD4 cell
counts at 1 year after ART initiation were available for
197 (66%), (63 with no worry and 134 with one or more
worries). There was no association between mean CD4
counts increases per year and reporting any worry at
the first assessment for ART eligibility (Table 4). Viral
load data after 1 year on ART was available for 180patients (54 with no worry and 126 with one worry or
more). Individuals who reported one worry or more
was associated with greater reductions in log viral load,
p<0.05. However this association was more marked
among individuals who were worried about HIV
serostatus disclosure and nutrition who had a greater
reduction compared to those without any of these wor-
ries p<0.05 for both). ART regimen change due to side
effects or treatment failure (substitution or switch) and
death were not associated with reporting a worry
(Table 4).
Discussion
Among participants assessed for ART eligibility in this
rural population based prospective cohort, small numbers
Table 4 Comparison of ART outcomes after 1 year between those with one or more worries and those without any
worry at the first eligibility assessment
















n=104 n=195 n=54 n=38 n=23 n=26 n=19 n=19
Total with CD4 counts after
ART eligibility
63 134 32 22 14 18 15 11
Mean CD4 counts increase
(per year) (95% CI)
162 199 112 127 97 363 189 156
(112-211) (129-270) (80-145) (87-167) (42-151) (-19-746) (56-322) (-31-343)
Median CD4 increase 92 114 73 112 74 122 115 168
(IQR) (47-212) (41-213) (41-183) (46-215) (40-106) (59-210) (33-232) (73-237)
Total with viral loads 54 126 33 24 14 16 15 12
CD4 count > 100 after
ART start
42 (78%) 95 (75%) 23 (70%) 16 (67%) 10 (71%) 10 (63%) 15 (100%) 12 (100%)
Annual decrease in median
log VL (IQR)
0.01 −0.10* −0.24* 0.04* 0.18 0.17 −0.14 0.05
(-0.10-0.12) (-0.19 - -0.02) (-0.41 - -0.07) (-0.12 - -0.21) (0.01-0.35) (0.12 - 0.33) (-0.49 - 0.20) (-0.02 - 0.30)
Number who started ART 104 195 51 38 23 24 19 19
Substituted / switched ART 29 (28%) 53 (27%) 16 (31%) 7 (18%) 6 (26%) 8 (33%) 3 (16%) 7 (37%)
Died 19 (18%) 13 (7%) 5 (10%) 4 (11%) 1 (4%) 1 (4%) 0 (0) 1 (5%)
*p<0.05 Note: Comparisons are between those with one or more worries and those with no worry, and also between those with a particular worry and all those
without that particular worry.
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had one worry or more. The commonest worries were
about fear of HIV serostatus disclosure, lack of food when
appetite improved on treatment, concurrent use of other
medications, ART adherence, problems concerning con-
dom use (either avoiding disclosing HIV serostatus, not
knowing how to use them, or reluctance to use them) and
ARV drug side effects. Patients who had one or more wor-
ries (particularly those who were worried of HIV
serostatus disclosure and lack of food when appetite im-
proved) had greater viral load reductions than those with
no worry. Among patients who had completed 24 months
on ART, patients who reported one or more worries had
made more scheduled ART refill visits than those with no
worry, but we found no association between annual CD4
cell increases and reporting worries.
A strength of this study is that we document patients’
worries before starting ART, and the prospective study
design allowed us to relate these worries to ART adher-
ence and treatment outcomes. Also being a rural setting,
our participant retention was high (over 92%), thus we
had minimal loss to follow up which was not different
between individuals who reported one worry or more
and those who reported no worry. However, our study
was limited by the small numbers of participants, and
since the data were collected from a single research site,
our findings may not be generalisable to other settings.
Another weakness is that we did not follow up orassess to ascertain if an individual who reported a
worry at the assessment for ART eligibility eventually
had problems related to that worry after starting on
ART. The two methods we used to assess ART adher-
ence (pill count and patients’ self-report) as outcome
measures have advantages and disadvantages; and nei-
ther is entirely reliable in determining a patient’s level
of ART adherence [20,21].
A Pubmed literature search did not reveal any studies
describing patients’ worries before initiating ART and
their association with treatment outcomes as most stud-
ies reported findings from patients who had already
started ART. It is therefore difficult to conclusively com-
pare our findings with those from studies done in pa-
tients who had already started on ART. In our study, we
did not find any association between fear of HIV
serostatus disclosure and ART adherence, but studies
among people already on ART have reported an associ-
ation between HIV serostatus disclosure and better ART
adherence [22,23]. Positive HIV serostatus disclosure to
one’s spouse or sexual partner is important in preventing
HIV transmission, may reduce patient’s stress, improves
psychological health and leads to informed reproductive
choices in couples where one or both are HIV positive
[24]. We did not follow up the patients who reported
worrying about HIV serostatus disclosure to ascertain
whether they later disclosed to their partners or not.
However, high HIV serostatus disclosure rates have been
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(94.5%), but these studies were also among individuals
already on ART [26].
In our study, the proportion of patients who reported
worries about lack of food after an improvement in ap-
petite after starting ART (12%) was lower than the pro-
portion (76%) reported in a study in Rwanda [27],
however the Rwanda study was among individuals who
had already initiated ART and their appetite possibly had
already started improving thus leading to more of their
patients being worried about lack of food.
Eight percent of our patients reported worry about
concurrent use of other medications. Although we did
not specifically ask what medications they were worried
about using concurrently with ARV drugs, some of them
may have been taking cotrimoxazole prophylaxis and/or
herbal or traditional medicines of unknown therapeutic
efficacy and interactions [28]. In Uganda, use of trad-
itional herbal medications is common and in one study
33.7% of patients on ART were also reported to be using
herbal medications for HIV associated symptoms [29].
Although we found no association between concurrent
use of herbal treatment and ART adherence, other stud-
ies found that use of herbal medications was associated
with ART non-adherence, though their use significantly
declined after six months on ART [30-32]. Although
only 6% of our participants reported worries about using
a condom, there is need to assess actual condom use in
our study population. However, our findings are collabo-
rated by findings from another study in Uganda that
reported a 70% reduction in risky sexual behaviour (de-
fined as inconsistent or no condom use with HIV-
negative or unknown HIV serostatus partners in the past
3 months) after 6 months on ART [33].
Participants may not be fully aware of the effects and
side effects of ART before they start on treatment, but
7% of our participants reported worries about adherence
to life-long ART. Since ART adherence is the main de-
terminant of treatment outcomes, our failure to find any
significant association between the mean annual CD4
count increases or viral load decreases and reporting
worries may be due to a true lack of an association be-
tween ART adherence and reported worries. However,
our finding that those participants who reported worries
had greater viral load suppression than those who did
not report any worry should be interpreted with cau-
tion due to the small numbers. We found that at base-
line patients who reported one worry or more were
less likely than those with no worries to be in WHO
clinical stages 3 or 4, i.e. to have a more advanced
stage of immunosuppression at ART eligibility assess-
ment. This would mean that patients reporting worries
might be more aware of, and concerned about, their
deteriorating health status and thus likely to presentfor ART eligibility assessment. We found no associ-
ation between deaths in patients on ART and reported
worries.
Since ART adherence is the main determinant of treat-
ment outcomes, our failure to find any significant differ-
ences either in the mean annual CD4 count increases or
viral load decreases between those who reported one worry
or more may be due to the lack of a significant association
between adherence to ARTand reported worries. Although
we found that patients who reported one or more worries,
and particularly those who were worried about HIV
serostatus disclosure and nutrition had greater viral load
suppression than those who did not report any worry or
these two particular worries, these findings should be
interpreted with caution due to the small numbers.
Conclusions
In spite of the lack of significant associations of worries
with unfavourable treatment outcomes, we detected a
number of anxieties that can cause stress and discomfort to
patients. Before and during ART initiation, physicians and
counsellors should be aware of the worries that patients
may have and assist patients in addressing them. Adoption
of routine couple counselling would help overcome the
worry of HIV serostatus disclosure to sexual partners and
would help identify HIV discordance. Food supplements
may be necessary for some patients initiating ART. Longer-
term assessment is needed to evaluate the potential impact
of addressing patients’ worries on the eventual adherence
and treatment outcomes of the life-long ART. There is also
need to follow-up patients who reported a specific worry at
the time of assessment of ART eligibility to ascertain if later
it became a reality after starting ART and also to examine
whether there were any differences in the specific causes of
death between those who had no worries and those who
had one worry or more.
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